BOULDER, Colo. and WASHINGTON, April 8, 2013 /PRNewswire/ -- BiOptix will present new and compelling PSA (Prostate-Specific Antigen) data from the BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology at the annual American Association for Cancer Research (AACR) meeting in Washington D.C., which is being held from April 6-10, 2013.
"The reason that BiOptix is here is to support cancer researchand the BiOptix 404pi is a new and innovative tool in this fight," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. Wilczek continued with a presentation of new and compelling PSA data that was generated on the BiOptix 404pi, regarded by the industry as a new generation of SPR instrumentation. "The kinetic data shown here demonstrate the instrument's sensitivity and ability to accurately measure and detect protein-protein as well as protein-small molecule interactions. The BiOptix 404pi is ideal for researchers and scientists who are on the front lines of cancer research, including drug discovery and development." Additional information about the BiOptix 404pi and the BiOptix Innovators Program, a unique to the industry instrumentation trial program, can be found at: http://www.bioptix.com/products/innovators-program
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interactionwith high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: http://www.bioptix.com